A film adapted from the real purchase of life-saving drugs, "I am not a drug god", let the word "generic drug" enter people's field of vision. The so-called generic drug, that is, after the end of the patent protection period of the patented drug, the alternative drug that is not copied by the pharmaceutical company that owns the patent.
The generic drug has the same therapeutic effect as the original drug, and at the same time, the generic drug becomes the choice for the patient to reduce the burden of medicine due to the relatively low price.
With the nationwide expansion of the volume purchase price negotiations, low-end generic generic drugs have entered the era of low profit, and new generic drugs and innovative drugs with high-tech barriers have become the strategic direction of pharmaceutical companies.
Pharmaceutical enterprises "abandon the pawn and protect the handsome" transformation of research and development products
The generic drug company Shijiazhuang Group has also begun to develop new targets such as macromolecular biopharmaceuticals, small molecule new drugs, and original chemical drugs, and generic drug research and development has also turned to high-tech generic drugs with high technology content.
At present, more than 4,700 pharmaceutical companies in China are basically developing generic drugs, and a small number of them are generic drugs plus innovative drugs. The raw materials and pharmaceutical companies and pharmaceutical companies that are related to the health care committee encourages the list will usher in a new wave of dividends, and Starting from 2020, a catalogue of drugs that encourage imitation will be released before the end of each year. At the same time, the generics market knockouts have intensified.
Conformity evaluation is a “comfort” for the purchase of generic drugs. It refers to the evaluation of quality consistency for the generic drugs that have been approved for marketing, in accordance with the principle of the quality and efficacy of the original drug, so that the generic drugs are in quality and efficacy. Achieve the same level as the original drug.
According to the public information, more than half of the varieties that have published the consensus evaluation R&D expenses are more than 5 million yuan. Therefore, the pharmaceutical companies with a large number of generic drug evaluation applications are relatively strong in China's pharmaceutical R&D strength and more varieties. Pharmaceutical companies with rich product lines, such as Qilu Pharmaceutical, Yangzijiang, China Biopharmaceutical, Hengrui Medicine and other enterprises.
The market for generic drugs will be strong and strong, and the weak will be weak. Enterprises with strong R&D capabilities and strong resource projects will occupy most of the market, while the weak may have limited funds for consistency evaluation and can only rely on existing ones. The chemical drug market survives.
"There are less than 300 pharmaceutical companies with R&D resources talent team platform capabilities. It is too early to say that the generic drug industry is reshuffled. The current volume of purchased products is still a small part in the entire pharmaceutical market, and a large number of chemical drugs are still available. Market demand."
"Many pharmaceutical companies are piles of products, even hundreds of thousands, but there are fewer and fewer competitive products." The current pharmaceutical companies must first clarify product strategies, from existing policies and opportunities. What to catch, such as children's medicine, or do oncology drugs, companies without research and development capabilities to buy projects, participate in the new generic drug market through acquisition cooperation. Focusing on the main business and highlighting the competitive advantage is also a trend of international pharmaceutical companies.
